Friday, June 29, 2018 4:06:25 PM
CRIS...June 11,2018 Curis, Inc. The biopharmaceutical company said it was granted a Phase I Small Business Innovation Research (SBIR) contract by the Department of Defense to develop its NSI-566 human neural stem cell line as a candidate therapeutic for severe Traumatic Brain Injury (TBI).
Daily
Daily
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
